Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 20, 2015, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.57 to $48,050,000.00.

Highlighted Stocks Traded by Insiders:

MKS Instruments (MKSI) - FREE Research Report

Anderson Robert R, who is Director at MKS Instruments, sold 500 shares at $35.85 on March 20, 2015. Following this transaction, the Director owned 19,337 shares meaning that the stake was reduced by 2.52% with the 500-share transaction.

The shares most recently traded at $35.98, up $0.13, or 0.37% since the insider transaction. Historical insider transactions for MKS Instruments go as follows:

  • 4-Week # shares bought: 1,161
  • 4-Week # shares sold: 825
  • 12-Week # shares bought: 1,161
  • 12-Week # shares sold: 10,596
  • 24-Week # shares bought: 1,161
  • 24-Week # shares sold: 30,636

The average volume for MKS Instruments has been 211,400 shares per day over the past 30 days. MKS Instruments has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are down 1.61% year-to-date as of the close of trading on Friday.

MKS Instruments, Inc. provides instruments, subsystems, and process control solutions that measure, control, power, monitor, and analyze critical parameters of manufacturing processes in the United States and internationally. The stock currently has a dividend yield of 1.83%. The company has a P/E ratio of 16.7. Currently, there are 3 analysts who rate MKS Instruments a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MKSI - FREE

TheStreet Quant Ratings rates MKS Instruments as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full MKS Instruments Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biocryst Pharmaceuticals (BCRX) - FREE Research Report

Babu Yarlagadda S, who is Senior VP - Drug Discovery at Biocryst Pharmaceuticals, sold 12,105 shares at $10.16 on March 20, 2015. Following this transaction, the Senior VP - Drug Discovery owned 148,697 shares meaning that the stake was reduced by 7.53% with the 12,105-share transaction.

The shares most recently traded at $9.29, down $0.87, or 9.36% since the insider transaction. Historical insider transactions for Biocryst Pharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 47,895
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 104,794
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 104,794

The average volume for Biocryst Pharmaceuticals has been 833,700 shares per day over the past 30 days. Biocryst Pharmaceuticals has a market cap of $739.5 million and is part of the health care sector and drugs industry. Shares are down 15.91% year-to-date as of the close of trading on Friday.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Currently, there are 5 analysts who rate Biocryst Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCRX - FREE

TheStreet Quant Ratings rates Biocryst Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. Get the full Biocryst Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CSG Systems International (CSGS) - FREE Research Report

Wiese Randy, who is Evp & Cfo at CSG Systems International, sold 2,000 shares at $29.46 on March 20, 2015. Following this transaction, the Evp & Cfo owned 153,324 shares meaning that the stake was reduced by 1.29% with the 2,000-share transaction.

The shares most recently traded at $30.59, up $1.13, or 3.69% since the insider transaction. Historical insider transactions for CSG Systems International go as follows:

  • 4-Week # shares sold: 54,543
  • 12-Week # shares sold: 58,563
  • 24-Week # shares sold: 98,563

The average volume for CSG Systems International has been 272,800 shares per day over the past 30 days. CSG Systems International has a market cap of $1.0 billion and is part of the technology sector and computer software & services industry. Shares are up 20.5% year-to-date as of the close of trading on Friday.

CSG Systems International, Inc. provides business support solutions primarily to the communications industry. The stock currently has a dividend yield of 2.33%. The company has a P/E ratio of 27.3. Currently, there are 2 analysts who rate CSG Systems International a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CSGS - FREE

TheStreet Quant Ratings rates CSG Systems International as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CSG Systems International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null